Compare PSFE & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PSFE | LCTX |
|---|---|---|
| Founded | 1996 | 1990 |
| Country | United Kingdom | United States |
| Employees | 2900 | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 390.7M | 391.1M |
| IPO Year | N/A | 1996 |
| Metric | PSFE | LCTX |
|---|---|---|
| Price | $8.52 | $1.65 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $8.69 | $5.33 |
| AVG Volume (30 Days) | 349.0K | ★ 992.3K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $14,556,000.00 |
| Revenue This Year | $8.26 | $109.40 |
| Revenue Next Year | $6.30 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 53.24 |
| 52 Week Low | $5.95 | $0.40 |
| 52 Week High | $16.49 | $2.09 |
| Indicator | PSFE | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 73.09 | 56.12 |
| Support Level | $7.71 | $1.56 |
| Resistance Level | $8.65 | $1.82 |
| Average True Range (ATR) | 0.37 | 0.07 |
| MACD | 0.18 | 0.02 |
| Stochastic Oscillator | 95.39 | 85.11 |
Paysafe Ltd is an integrated payments platform. Its core purpose is to enable businesses and consumers to connect and transact seamlessly through capabilities in payment processing, digital wallet, and online cash solutions. The company provides payment solutions through three primary lines of business: Integrated Processing, Digital Wallet and eCash Solutions. It derives a majority of revenue from the USA followed by Germany, the UK, and all other countries.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.